APA

Shi W., Jiang T., Nuciforo P., Hatzis C., Holmes E., Harbeck N., Sotiriou C., Peña L., Loi S., Rosa D. D., Chia S., Wardley A., Ueno T., Rossari J., Eidtmann H., Armour A., Piccart-Gebhart M., Rimm D. L., Baselga J. & Pusztai L. (20180501). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa D D, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm D L, Baselga J and Pusztai L. 20180501. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Shi W., Jiang T., Nuciforo P., Hatzis C., Holmes E., Harbeck N., Sotiriou C., Peña L., Loi S., Rosa D. D., Chia S., Wardley A., Ueno T., Rossari J., Eidtmann H., Armour A., Piccart-Gebhart M., Rimm D. L., Baselga J. and Pusztai L. (20180501). Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa D D, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm D L, Baselga J and Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. : Annals of oncology : official journal of the European Society for Medical Oncology. 20180501.